James Pan
Fondateur chez Exacis Biotherapeutics, Inc.
Profil
James Pan is the founder and Head of Discovery & Development at Exacis Biotherapeutics, Inc. which was founded in 2020.
He is currently the Chief Executive Officer & Director at China Immunotech (Beijing) Biotechnology Co., Ltd.
Dr. Pan holds a doctorate degree from the University of Toronto.
Postes actifs de James Pan
| Sociétés | Poste | Début |
|---|---|---|
Exacis Biotherapeutics, Inc.
 Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | Fondateur | 01/01/2020 |
China Immunotech (Beijing) Biotechnology Co., Ltd.
 China Immunotech (Beijing) Biotechnology Co., Ltd. BiotechnologyHealth Technology China Immunotech (Beijing) Biotechnology Co., Ltd. is a biotechnology company based in Beijing, China. The company's description is written in a mix of Chinese and English, making it difficult to understand. The company was founded in 2018 by Xue Qiang Zhao, Hong Li Zheng, Wei Rui, and Wei Rui has been the CEO since 2018. | Directeur Général | - |
Formation de James Pan
| University of Toronto | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
China Immunotech (Beijing) Biotechnology Co., Ltd.
China Immunotech (Beijing) Biotechnology Co., Ltd. BiotechnologyHealth Technology China Immunotech (Beijing) Biotechnology Co., Ltd. is a biotechnology company based in Beijing, China. The company's description is written in a mix of Chinese and English, making it difficult to understand. The company was founded in 2018 by Xue Qiang Zhao, Hong Li Zheng, Wei Rui, and Wei Rui has been the CEO since 2018. | Health Technology |
Exacis Biotherapeutics, Inc.
Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | Health Services |